Haploidentical donors are increasingly used for patients requiring hematopoietic stem cell transplantation (HSCT). Although several factors have been associated with the results of transplantation, the impact of HLA disparity haploidentical HSCT (haplo-HSCT) is unclear. We investigate the impact of HLA disparity is measured by eplets mismatched (ME) load each HLA locus on the clinical outcome of 278 consecutive haploidentical transplantation.
Here, we show that the level of mismatch of HLA molecules, the HLA locus of an individual, may be relevant to clinical outcomes in haplo-HSCT. A survival is significantly better overall was associated with a higher load ME of HLA-A (hazard ratio [HR], 0.97; 95% confidence interval [CI], from 0.95 to 0.99; P = 0.003 ) and class I loci (HR, 0.99; 95% CI, 0.97 to 0.99; P = 0.045) in the direction of host-versus-graft. Clear survival advantage HLA-A ME mainly due to a decrease in the risk of relapse associated with an increase in HLA-A ME load (subdistribution HR, 0.95; 95% CI, from 0.92 to 0.98; P = 0.004).
In addition, we have identified a link between risk of disease grade 3-4 acute graft-versus-host (GVHD) and higher load in the ME-B and HLA class I loci (gvh) direction of graft-versus-host. Additionally, gvh nonpermissive HLA-DPB1 mismatch is defined by a T-cell epitope grouping was significantly associated with relapse protection (subdistribution HR, 0.19; 95% CI, 0.06 to 0.59; P = 0.004) without a concurrent increase in GVHD.
These findings indicate that alloreactivity generated by the HLA abnormalities in certain HLA loci associated with the results of transplantation, and analysis of individual HLA locus ME donor selection and may help in the risk stratification haplo-HSCT.

Anti-Human Leukocyte Antigen Exchange cryopreserved allograft immune sensitivity and Blood Transfusion
ALLOTRANSPLANTATION vascularization composite (VCA) is the most advanced reconstructive techniques are available for patients suffering from burns destroy all the limbs or face. However, VCA require donor-recipient matching. Burn patients have been reported to experience sensitization, or the development of antibodies anti-human leukocyte antigen, during resuscitation and wound coverage, potentially deprive them of VCA future.
This study sought to investigate the contribution of blood and allograft for sensitization in burn patients. Four groups were compared: burn patients who receive blood products and allograft (group 1), burn patients who receive blood products alone (group 2), trauma patients who received blood products alone (group 3), and control healthy volunteers (group 4) , The average is calculated panel-reactive antibody (indicating sensitization) were higher in group 1 than in group 4 (P = 0.035). In addition, the incidence of severe sensitization was higher in group 1 relative to the other groups (P = 0.049).
When comparing the group of patients who do not have the sensitivity, sensitization light, sensitization medium, and sensitization worse, there was no significant difference in age, sex, blood products received, body surface area total burned, or allograft is used between the groups, although highly sensitized patients tend to have a total body surface area involvement greater and receive more units of packed red blood cells and allografts (P = 0.079, P = 0.196 and P = 0.072, respectively). Therefore, we conclude that while burn patients who received allograft and blood showed a higher incidence of anti-human leukocyte antigen sensitization relative to healthy controls, this difference can not be solely attributed to both allograft use or transfusions.



